Krishna Institu. Q1 FY27 Earnings Call — Analysis (NSE: KIMS)

KIMS delivers 35% YoY consolidated revenue growth in Q1FY27, driven by strong IP/OP volumes and ramp-up of new hospitals; QIP and promoter infusion strengthen balance sheet, reducing debt by ₹1,100 Cr.

8 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Consolidated EBITDA pre-Ind AS (excl. o… ₹206 Cr ( +10.2% YoY ) . New guidance — FY28 and FY30-31 kerala cluster ebitda margin mid-teens for FY28; 20%–22% . New story: Capacity-led growth and new hospital ramp-up .

Results

Consolidated revenue from operations ₹1,180 Cr (+35.3% YoY); EBITDA pre-Ind AS ₹222 Cr (+14.6% YoY); PAT ₹37 Cr vs ₹85 Cr in Q1FY26; IP volumes +26.6% YoY, OP volumes +28.5% YoY; ARPOB +9.7% YoY; debt reduced to ~₹2,400 Cr.

Financial highlights

Guidance

Management aims to sustain historical YoY top-line and bottom-line growth; new hospitals targeted for EBITDA neutrality in FY27; Kerala cluster guided to mid-teens margin in FY28 and 20–22% in 2–3 years; Kondapur hospital seen reaching ₹1,200 Cr revenue in 4–5 years.

What management committed to

• The [Thrissur] hospital will be commissioned within the next three to four months. — Q3FY27
• [Management's] priority is to neutralize EBITDA in most of the hospitals that were commissioned last year [FY26]. — FY27
• The [Kerala cluster] will move to mid-teens EBITDA margin next financial year [FY28] and should stabilize at around 20%–22% over the next two to three years. — mid-teens for FY28; 20%–22%, FY28 and FY30-31
• The [Telangana cluster] can ramp up to 70% [bed occupancy] in spite of the new Kondapur hospital and the new Secunderabad hospital over the next three to four years. — 70%, FY30
• Most of the key insurance empanelments for the four new assets [Thane, Nashik, Mahadevapura, Electronic City] will be completed by end of August, mid-September [2026]. — Q2FY27
• The [Bangalore cluster] is aiming to be zero EBITDA for the full year [FY27], with no losses. — zero EBITDA, FY27
• [KIMS] intends to keep its debt equity in the range of 2.5:1. — 2.5:1, ongoing
• The full potential of the [new Kondapur] hospital will be around INR 100 crore revenue per month, which is around INR 1,200 crore revenue, achievable over the next four, five years. — INR 100 crore per month / INR 1,200 crore revenue, FY31-32
• Maintenance CAPEX would be around INR 100 crore per year for the next three or four years. — INR 100 crore per year, FY27-FY30
• Total capital expenditure in the next nine months from these three assets [Secunderabad, Rajahmundry, Kondapur] will be about INR 100–125 crore. — INR 100–125 crore, FY27

Key themes

New hospital ramp-up and balance sheet strengthening

How the narrative shifted

• Capacity-led growth and new hospital ramp-up: Management is aggressively expanding bed capacity, with new hospitals ramping faster than expected (Mahadevapura breakeven, Thane improving) and Kondapur expansion poised to become the largest revenue generator.
• Balance sheet deleveraging: QIP and promoter infusion used to retire ₹1,100 Cr debt, lowering leverage; management intends to maintain D/E around 2.5x and deploy internal accruals for growth.
• Empanelment progress unlocking demand: Key insurance empanelments are being completed for new assets, with remaining expected by mid-September, which will boost volumes and partially normalise ARPOB.
• Margin normalisation trajectory: Margins are temporarily suppressed by newer units and pre-operative costs, but management sees a clear path to 30-35% EBITDA in Telangana and 20-22% in Kerala over 2-4 years.
• Complex care case-mix uplift: Quaternary and complex surgeries (lung transplants, robotic cardiac, novel aortic techniques) are lifting ARPOB and ARPP, especially in Bangalore, enhancing revenue intensity.
• Core market focus, no new geographies: Future expansion will remain within existing core states (Maharashtra, Karnataka, Kerala, Telangana, Andhra) via greenfield and O&M/acquisitions, avoiding unrelated diversification.

Operational commentary

• New Kondapur hospital commissioned in June 2026; first full month (July) achieved 40% revenue growth to ₹45 Cr; full potential seen at ₹1,200 Cr revenue (₹100 Cr per month) in 4–5 years.
• Mahadevapura (Bangalore) achieved EBITDA breakeven in June 2026; July revenue ₹20 Cr; overall Bangalore cluster targeted for zero EBITDA in FY27.
• Thane hospital gained GIPSA and oncology empanelment in May–June; July revenue jumped to ₹21 Cr with 10% EBITDA margin; Q2 breakeven expected if trend persists.
• Thrissur greenfield in Kerala on track to commence in 3–4 months; Kerala cluster currently at single-digit margin, guided to mid-teens in FY28 and 20–22% in 2–3 years.
• O&M agreements signed for two hospitals: a 300-bed facility near Kondapur (revenue potential ₹90–95 Cr/month) and a Kakinada hospital (current ₹7–8 Cr/month, scalable to ₹15–20 Cr).
• Empanelments: ~50% of key insurers empanelled at Thane, Nashik, and two Bangalore assets; remaining targeted for completion by end-Aug/mid-Sep 2026, improving patient footfall.
• Secunderabad renovation: 200 beds non-operational; new facility expected by end of FY28; excluding non-operational beds, Telangana occupancy already at ~61%.
• Capex for next nine months estimated at ₹100–125 Cr across Secunderabad, Rajahmundry greenfield, and Kondapur; maintenance capex pegged at ~₹100 Cr p.a. for 3–4 years.

Analyst Q&A

• Q. What is the progress on the common empanelment initiative (JIC)?

  I think lesser spoken about that in a common forum is better for the industry as such... we should do it on a one-on-one basis than to discuss in a public forum on JIC. Some clarity is emerging, insurance companies are getting clarity, and things should settle down over the next few months.

• Q. What is the overall margin trajectory for H2 FY27 and FY28?

  We will share a note on that separately after the call. We won't be having an end to this.

• Q. Why did Thane's ramp-up flatten out, and when will it achieve breakeven?

  Q1 is traditionally weak in Maharashtra, delayed empanelments constrained growth. July revenue reached ₹21 Cr with 10% EBITDA margin; if August–September continue similarly, it should deliver healthy EBITDA margin for Q2.

• Q. What is the sustainable margin for Telangana long-term?

  30–35% EBITDA margin is achievable; mature hospitals like Secunderabad already do 34–35%. With new bed additions, it will take some time to return to 30%-plus, but the path is clear.

View source

Research and educational content only. Not investment advice.